Protective mechanical ventilation in patients with risk factors for ARDS: prospective cohort study

Cristiane Bastos-Netto1, Maycon Moura Reboredo1,2, Rodrigo Souza Vieira1, Lidia Maria Carneiro da Fonseca1,2, Erich Vidal Carvalho1,2, Marcelo Alcantara Holanda3,4, Bruno Valle Pinheiro1,2

ABSTRACT

Objective: To evaluate the association that protective mechanical ventilation (MV), based on VT and maximum distending pressure (MDP), has with mortality in patients at risk for ARDS. Methods: This was a prospective cohort study conducted in an ICU and including 116 patients on MV who had at least one risk factor for the development of ARDS. Ventilatory parameters were collected twice a day for seven days, and patients were divided into two groups (protective MV and nonprotective MV) based on the MDP (difference between maximum airway pressure and PEEP) or VT. The outcome measures were 28-day mortality, ICU mortality, and in-hospital mortality. The risk factors associated with the adoption of nonprotective MV were also assessed. Results: Nonprotective MV based on VT and MDP was applied in 49 (42.2%) and 38 (32.8%) of the patients, respectively. Multivariate Cox regression showed that protective MV based on MDP was associated with lower in-hospital mortality (hazard ratio = 0.37; 95% CI: 0.19-0.73) and lower ICU mortality (hazard ratio = 0.40; 95% CI: 0.19-0.85), after adjustment for age, Simplified Acute Physiology Score 3, and vasopressor use, as well as the baseline values for PaO2/FiO2 ratio, PEEP, pH, and PaCO2. These associations were not observed when nonprotective MV was based on the VT. Conclusions: The MDP seems to be a useful tool, better than VT, for adjusting MV in patients at risk for ARDS.

Keywords: Respiration, artificial; Tidal volume; Respiratory distress syndrome, adult.

INTRODUCTION

Although mechanical ventilation (MV) is an essential supportive measure for patients with severe respiratory failure,1,2 it can cause lung injury characterized by inflammatory infiltrates and hyaline membranes, as well as alveolar and interstitial edema, being designated ventilator-induced lung injury (VILI).3

Previously injured lungs, as in ARDS, are more susceptible to VILI,4 and in such cases, lung-protective ventilator settings, such as reducing VT to ≤ 6 mL/kg of predicted body weight and plateau pressure to ≤ 30 cmH2O, are associated with lower mortality.5-7 Amato et al.,8 demonstrated that distending pressure (DP, i.e., plateau pressure minus PEEP) correlated better with mortality than did VT, plateau pressure, or PEEP. This correlation was confirmed by Bellani et al.,9 and a DP of < 14-15 cmH2O has been recommended as a lung-protective ventilation strategy in ARDS.10

Although experimental studies have shown that VILI can occur in previously normal lungs,11,12 the impact of lung-protective MV on patients without ARDS is controversial. In a randomized clinical trial in patients without ARDS, Determann et al.13 showed that low VT resulted in a lower occurrence of VILI. However, in another randomized clinical trial in patients without ARDS, no differences were found between patients receiving ventilation with a low VT and those receiving ventilation with a high VT regarding mortality and duration of MV.14

Observational studies have evaluated the impact of DP on mortality in patients without ARDS; however, the results have been conflicting. Although Simonis et al. showed an association between an increased DP and ICU mortality,15 Schmidt et al. found no association between DP and in-hospital mortality in patients without ARDS.16 One limitation of these studies was that maximum airway pressure was assumed to be equivalent to plateau pressure in patients receiving pressure-controlled ventilation and was used in order to calculate DP. Maximum airway pressure is necessarily greater than plateau pressure, and we propose that the term maximum DP (MDP) be used in order to refer to the difference between maximum airway pressure and PEEP.

One possible explanation for these conflicting results is that mechanically ventilated patients without ARDS can present with a variety of clinical conditions requiring ventilatory support, all of which can differ in terms of the risk for VILI. Given that VILI ultimately results in an inflammatory lung injury that is similar to ARDS, it is to
Protective mechanical ventilation in patients with risk factors for ARDS: prospective cohort study

be expected that VILI is more likely to occur in patients without ARDS with one or more risk factors for ARDS than in those with no risk factors for ARDS.\(^{(17)}\) The primary objective of this prospective cohort study was to evaluate the association that protective MV (based on \(V_t\) and MDP) has with mortality in patients at risk for ARDS. A secondary objective was to identify factors associated with nonprotective MV in these patients.

**METHODS**

This was a prospective cohort study conducted between May of 2016 and March of 2018 in the ICU of the Hospital Universitário da Universidade Federal de Juiz de Fora (HU-UFJF, Federal University of Juiz de Fora University Hospital), located in the city of Juiz de Fora, Brazil. The HU-UFJF ICU is a 9-bed medical-surgical ICU for adult patients. The study followed the principles of the Declaration of Helsinki and was approved by the Human Research Ethics Committee of the HU-UFJF (Ruling no. 2,494,061). Close relatives of the patients gave written informed consent.

**Study cohort**

The inclusion criteria were being \(\geq 18\) years of age, having been admitted to the ICU, being on MV, and having at least one of the following risk factors for ARDS: pneumonia, sepsis, shock, aspiration of gastric contents, pancreatitis, blood component transfusion, trauma, pulmonary contusion, and lung injury caused by inhalation or near drowning. The exclusion criteria were as follows: having been diagnosed with ARDS in accordance with the Berlin Definition of ARDS\(^{(18)}\) within two days of endotracheal intubation; having been transferred from another hospital while on MV; having been on MV for less than 48 h; and having been started on palliative care by decision of the treatment team.

All patients were ventilated with a Servo-S ventilator (Maquet, Solna, Sweden), initially in pressure-controlled mode. Patients were switched to pressure support ventilation if they were awake and stable, as evaluated by the treatment team.

**Variables**

Data on baseline clinical and demographic characteristics were collected at ICU admission for the Simplified Acute Physiology Score 3 (SAPS 3) and SOFA, as were data on diagnosis at admission and comorbidities. The day of endotracheal intubation was designated day 0, the following data being recorded: reason for intubation, risk factors for ARDS, the SAPS 3, SOFA scores, predicted body weight—weight = 50.0 + 0.91 \(\times\) (height in cm - 152.4) for males and weight = 45.5 + 0.91 \(\times\) (height in cm - 152.4) for females—BMI, ventilatory parameters, and arterial blood gases.

From MV day 1 to MV day 7, ventilatory parameters were collected daily at 8:00 a.m. and 8:00 p.m., as were data on the use of vasopressors, corticosteroids, and neuromuscular blocking agents while on MV. Data on 28-day mortality, ICU mortality, and in-hospital mortality were also collected.

The exposure variable was whether or not protective MV based on \(V_t\) was used within the first 7 days of MV. Protective MV based on \(V_t\) was considered to have been provided when the \(V_t\) was found to be lower than 8 mL/kg of predicted body weight in at least 80% of the 14 measurements performed within the first 7 days of MV. A second exposure variable was whether protective MV based on MDP (difference between maximum airway pressure and PEEP) was used within the first 7 days of MV. Protective MV based on MDP was considered to have been provided when the MDP was found to be lower than 15 cmH\(_2\)O in at least 80% of the 14 measurements performed within the first 7 days of MV. MV was also considered to be protective when it met the criteria for protective MV as defined by both the \(V_t\) and the MDP.

**Outcome measures**

The outcome measures were 28-day mortality, in-hospital mortality, and ICU mortality.

**Statistical analysis**

The results are presented as mean and standard deviation, median and interquartile range, or proportions, as appropriate. For continuous variables with normal distribution, the groups protective MV and nonprotective MV were compared by the Student’s \(t\)-test; for continuous variables with non-normal distribution, they were compared by the Wilcoxon test, the Shapiro-Wilk test being used in order to determine the distribution of the variables. For categorical variables, the groups were compared by the chi-square test.

Multivariate Cox regression was used in order to estimate the hazard ratio (HR) for 28-day mortality, ICU mortality, and in-hospital mortality as a function of whether or not protective MV had been used. The HR was adjusted for age, SAPS 3, use of vasopressors, the PaO\(_2\)/FiO\(_2\) ratio, PEEP, respiratory system compliance (C\(_{rs}\)), \(pH\), and PaCO\(_2\).

Multivariate logistic regression was performed to analyze factors independently associated with the use of nonprotective MV, all of the variables showing \(p < 0.2\) in the univariate analysis being included in the multivariate analysis. The coefficients were estimated by the maximum likelihood method.

Values of \(p < 0.05\) were considered statistically significant. All analyses were performed with the Stata statistical package, version 15.1 (StataCorp LP, College Station, TX, USA).

**RESULTS**

During the study period, 258 patients were admitted to the HU-UFJF ICU. Of those, 148 met the inclusion criteria. Of those, 32 were excluded, the study cohort therefore consisting of 116 patients. The main reason...
for exclusion was having been started on palliative care by decision of the treatment team. As can be seen in Figure 1, nonprotective MV based on VT was used in 49 patients (42.2%; 95% CI: 33.5-51.1%) and nonprotective MV based on MDP was used in 38 (32.8%; 95% CI: 24.7-41.9%).

The main baseline characteristics of the patients are summarized in Table 1. The mean age was 59.3 ± 17.7 years, and the SAPS 3 at ICU admission was 49.9 ± 15.8. Major risk factors for ARDS included shock, in 71 patients (61.2%), sepsis, in 68 (58.6%), and pneumonia, in 27 (23.3%); a total of 66 patients (56.9%) had more than one risk factor for ARDS. Table 2 shows the outcomes of patients receiving protective or nonprotective MV based on VT and MDP.

At baseline, patients receiving protective MV based on VT had lower severity scores (SAPS 3), higher predicted body weight, higher pH values, and lower FiO2 than did those receiving nonprotective MV (Table 1). Protective MV based on VT was not associated with lower in-hospital mortality, ICU mortality, or 28-day mortality (Tables 3 and 4). Given that sample size was not initially calculated, the power of the study to detect an association between protective MV based on VT and ICU mortality was calculated. On the basis of the number of patients included in the study (N = 116) and the results obtained (HR = 0.72), with p < 0.05 being considered significant, the power of the study to detect an association between protective MV based on VT and ICU mortality was 39%. The following variables were independently associated with nonprotective MV based on the VT: the SAPS 3 at admission, predicted body weight, and the \( \frac{\text{PaO}_2}{\text{FiO}_2} \) ratio (Table 5).

Patients receiving protective MV based on MDP had higher \( C_{\text{pa}} \), better gas exchange (higher \( \frac{\text{PaO}_2}{\text{FiO}_2} \) and lower \( \text{PaCO}_2 \)), and higher pH values, as well as requiring lower FiO2 and PEEP (Table 1). After adjustment for covariates, protective MV based on MDP was associated with lower in-hospital mortality, ICU mortality, and 28-day mortality (Tables 3 and 4). On the basis of the number of patients included in the study (N = 116) and the results obtained (HR = 0.68), with p < 0.05 being considered significant, the power of the study to detect an association of protective MV based on MDP with mortality was 43%. The following variables were independently associated with nonprotective MV based on the MDP: pneumonia as the reason for initiating MV, \( C_{\text{pa}} \), the \( \frac{\text{PaO}_2}{\text{FiO}_2} \) ratio, and pH (Table 5).

When protective MV was defined on the basis of both the VT and the MDP, it was significantly associated with 28-day mortality, although not with in-hospital mortality or ICU mortality (Tables 3 and 4).

**DISCUSSION**

In the present study, no association was found between lower mortality and protective MV based on a VT of < 8 mL/kg of predicted body weight in more than 80% of the measurements performed within the first 7 days of ventilatory support in patients at risk for ARDS. However, when protective MV was defined on the basis of an MDP of < 15 cmH\(_2\)O, it was associated with lower in-hospital mortality, ICU mortality, and 28-day mortality.

Although it is well established that protective MV reduces mortality in patients with ARDS,\(^{6,7}\) the benefits of protective MV in patients without ARDS remain controversial. In a meta-analysis of randomized clinical trials and observational studies conducted in ICUs or during major surgery, protective MV with low VT was associated with better clinical outcomes in patients without ARDS, including lower mortality and lower occurrence of lung infection and injury.\(^{19}\) However, in a clinical trial of patients without ARDS, no differences in mortality (ICU mortality, in-hospital mortality, and 28-day mortality) were found.

**Figure 1.** Cohort study flow chart. MV: mechanical ventilation.
Table 1. Baseline characteristics of patients receiving protective or nonprotective mechanical ventilation.

| Group                  | Total sample (N = 116) | Protective MV (n = 67) | Nonprotective MV (n = 49) | p   | Protective MV (n = 78) | Nonprotective MV (n = 38) | p   |
|------------------------|------------------------|------------------------|---------------------------|-----|------------------------|---------------------------|-----|
| **Age, years**         | 59.3 ± 17.7            | 57.0 ± 18.2            | 62.3 ± 16.7               | 0.108 | 57.6 ± 18.6            | 62.6 ± 15.2               | 0.152 |
| **Males**              | 65 (56.0)              | 44 (65.7)              | 21 (42.9)                 | 0.140 | 47 (60.3)              | 18 (47.4)                 | 0.189 |
| **SAPS 3 at admission**| 49.9 ± 15.8            | 46.8 ± 15.2            | 54.3 ± 15.8               | 0.011 | 48.7 ± 15.8            | 52.4 ± 15.9               | 0.247 |
| **SOFA at admission**  | 7.8 ± 3.7              | 7.7 ± 3.5              | 8.0 ± 3.9                 | 0.741 | 7.7 ± 3.7              | 8.0 ± 3.6                 | 0.684 |
| **BMI, kg/m²**         | 22.5 [19.0-27.0]       | 22.3 [19.6-26.3]       | 23.3 [18.0-28.3]          | 0.789 | 22.2 [18.8-25.6]       | 23.6 [20.9-28.3]          | 0.171 |
| **Predicted body weight, kg** | 58.5 ± 10.3         | 61.7 ± 9.1             | 54.2 ± 10.5               | < 0.001 | 58.9 ± 10.7           | 57.7 ± 9.8                | 0.549 |
| **Reason for ICU admission** | 0.872                         |                         |                          |       | 0.715                               |
| **Clinical**           | 95 (81.9)              | 55 (82.1)              | 40 (81.6)                 | 0.001 | 63 (80.8)              | 32 (84.2)                 | 0.122 |
| **Elective surgery**   | 13 (11.2)              | 8 (11.9)               | 5 (10.2)                  | 0.001 | 10 (12.8)              | 3 (7.9)                   | 0.031 |
| **Urgent surgery**     | 8 (6.9)                | 4 (6.0)                | 4 (8.2)                   | 0.001 | 5 (6.4)                | 3 (7.9)                   | 0.031 |
| **Risk factor for ARDS** |                          |                         |                           |       |                        |                           |     |
| **Pneumonia**          | 27 (23.3)              | 16 (23.9)              | 11 (22.5)                 | 0.057 | 14 (17.9)              | 13 (34.2)                 | 0.052 |
| **Sepsis**             | 68 (58.6)              | 38 (56.7)              | 30 (61.2)                 | 0.626 | 47 (60.3)              | 21 (55.3)                 | 0.608 |
| **Shock**              | 71 (61.2)              | 37 (55.2)              | 34 (69.4)                 | 0.122 | 46 (59.0)              | 25 (65.8)                 | 0.480 |
| **Aspiration**         | 4 (3.5)                | 4 (5.9)                | 0 (0.0)                   | 0.082 | 3 (3.9)                | 1 (2.6)                   | 0.737 |
| **Blood product transfusion** | 21 (18.1)            | 10 (14.9)              | 11 (22.5)                 | 0.371 | 14 (18.0)              | 7 (18.4)                  | 0.951 |
| **Other**              | 10 (8.6)               | 6 (8.9)                | 4 (8.2)                   | 0.881 | 8 (10.3)               | 2 (5.3)                   | 0.368 |
| **Number of risk factors** | 0.399                          |                         |                           |       | 0.464                               |
| 1                      | 50 (43.1)              | 32 (47.8)              | 18 (36.7)                 | 0.001 | 34 (44.0)              | 16 (42.1)                 | 0.031 |
| 2                      | 47 (40.5)              | 26 (38.8)              | 21 (42.9)                 | 0.001 | 33 (42.3)              | 14 (36.8)                 | 0.031 |
| 3                      | 18 (15.5)              | 8 (11.9)               | 10 (20.4)                 | 0.001 | 11 (14.1)              | 7 (18.4)                  | 0.031 |
| 4                      | 1 (0.9)                | 1 (1.5)                | 0 (0.0)                   | 0.001 | 0 (0.0)                | 1 (1.4)                   | 0.001 |
| **MV (day 0)**         | 0.5 [0.4-0.6]          | 0.45 [0.4-0.6]         | 0.5 [0.4-0.7]             | 0.027 | 0.4 [0.4-0.5]          | 0.6 [0.5-0.7]             | <0.001 |
| **FR, breaths/min**    | 18 [16-22]             | 20 [16-22]             | 17 [16-20]                | 0.049 | 18 [16-21]             | 18 [16-22]                | 0.608 |
| **Vt/predicted body weight, mL/kg** | 7.5 ± 1.4            | 6.9 ± 1.1              | 8.3 ± 1.4                 | < 0.001 | 7.5 ± 1.5           | 7.4 ± 1.4                 | 0.617 |
| **MDP, cmH₂O**         | 14.5 ± 3.4             | 14.3 ± 3.4             | 14.8 ± 3.5                | 0.447 | 13.5 ± 3.0             | 16.6 ± 4.1                | <0.001 |
| **Paw max, cmH₂O**     | 20.6 ± 4.5             | 20.5 ± 4.7             | 21.0 ± 4.4                | 0.565 | 19.3 ± 3.7             | 23.5 ± 5.0                | <0.001 |
| **PEEP, cmH₂O**        | 5 [5-7]                | 5 [5-6]                | 6 [5-7]                   | 0.117 | 5 [5-6]                | 6 [5-7]                   | 0.019 |
| **Crs, mL/cmH₂O**      | 31.8 ± 10.3            | 31.5 ± 9.8             | 32.2 ± 11.0               | 0.712 | 33.7 ± 10.1            | 27.7 ± 9.5                | <0.001 |
| **Arterial blood gas analysis (day 0):** |                                           |                       |                           |       |                        |                           |     |
| **pH**                 | 7.34 ± 0.11            | 7.36 ± 0.11            | 7.32 ± 0.1                | 0.032 | 7.36 ± 0.11           | 7.30 ± 0.10               | 0.005 |
| **PaCO₂, mmHg**        | 289.0 ± 104.0          | 301.8 ± 96.0           | 272.5 ± 112.1             | 0.134 | 320.0 ± 98.0          | 224.0 ± 85.0              | <0.001 |
| **PaO₂, mmHg**         | 38.5 ± 11.6            | 38.7 ± 10.6            | 38.2 ± 12.9               | 0.803 | 36.2 ± 9.1            | 43.3 ± 14.4               | 0.002 |

MDP: maximum distending pressure; SAPS 3: Simplified Acute Physiology Score 3; MV: mechanical ventilation; Paw max: maximum airway pressure; and Crs: respiratory system compliance. *Values expressed as n (%), mean ± SD, or median [IQR].
mortality, 28-day mortality, or 90-day mortality), duration of MV, or ICU length of stay were found between patients randomized to MV with low VT (4-6 mL/kg of predicted body weight) and those randomized to MV with high VT (10 mL/kg of predicted body weight). In an observational study of a cohort of 935 patients without ARDS, no correlations were found between VT and mortality. These results are consistent with ours and constitute evidence against the use of low VT in mechanically ventilated patients without ARDS.

One possible explanation for the lack of association between lower VT and better outcomes in patients without ARDS is that such patients have higher C\textsubscript{p}, which can reduce the risk of injury even if they receive MV with high VT. Therefore, DP (or MDP, as in our study) might be better than VT to adjust MV for lung-protective ventilation in patients without ARDS. DP is calculated by dividing VT by static compliance of the respiratory system. Therefore, whenever compliance is reduced, translating to greater pulmonary involvement, VT should be reduced for protective MV based on the DP. A randomized clinical trial corroborated this hypothesis, showing no differences between MV with low VT and MV with intermediate VT regarding the outcomes of patients without ARDS, with the levels of DP in both groups being protective against VILI (11 cmH\textsubscript{2}O in the low VT group and 13 cmH\textsubscript{2}O in the intermediate VT group).

In our study, protective MV based on the MDP correlated with lower mortality, suggesting that MDP is an important parameter to be considered for protective MV in patients without ARDS. The association between protective MV and mortality was found to be worse

### Table 2. Outcomes of patients receiving protective or nonprotective mechanical ventilation.\(^a\)

| Variable                        | Total sample (n = 116) | Protective MV (n = 67) | Nonprotective MV (n = 49) | p    | Protective MV (n = 78) | Nonprotective MV (n = 38) | p    |
|---------------------------------|------------------------|------------------------|--------------------------|------|------------------------|--------------------------|------|
| Use of vasopressors             | 100 (86.2)             | 56 (83.6)              | 44 (89.8)                | 0.338| 65 (83.3)              | 35 (92.1)                | 0.198|
| Use of corticosteroids          | 90 (77.6)              | 49 (73.1)              | 41 (83.7)                | 0.179| 57 (73.1)              | 33 (86.8)                | 0.095|
| Use of neuromuscular blocking agents | 19 (16.4)              | 11 (16.4)              | 8 (16.3)                 | 0.990| 7 (9.0)                | 12 (31.6)                | 0.002|
| 28-day mortality               | 35 (30.2)              | 14 (20.9)              | 21 (42.9)                | 0.011| 19 (24.4)              | 16 (42.1)                | 0.051|
| ICU mortality                   | 47 (40.5)              | 22 (32.9)              | 25 (51.0)                | 0.049| 23 (29.5)              | 24 (63.2)                | 0.001|
| In-hospital mortality           | 59 (50.9)              | 28 (41.8)              | 31 (63.3)                | 0.22 | 30 (38.5)              | 29 (76.3)                | < 0.001|

### Table 3. Univariate Cox regression for the association of mortality with protective mechanical ventilation based on VT, on maximum distending pressure, and on both.

| Outcome                         | VT\(^a\)                | Protective MV based on MDP\(^b\) | Both the VT and the MDP | p     | HR (95% CI) | p     | HR (95% CI) | p     |
|---------------------------------|-------------------------|---------------------------------|-------------------------|-------|-------------|-------|-------------|-------|
| In-hospital mortality           | 0.63 (0.37-1.05)        | 0.60 (0.36-1.01)                | 0.46 (0.29-0.93)        | 0.03  |
| ICU mortality                   | 0.72 (0.40-1.28)        | 0.49 (0.27-0.88)                | 0.60 (0.30-1.21)        | 0.151 |
| 28-day mortality                | 0.44 (0.22-0.86)        | 0.56 (0.29-1.11)                | 0.38 (0.17-0.83)        | 0.016 |

### Table 4. Multivariate Cox regression for the association of mortality with protective mechanical ventilation based on VT, on maximum distending pressure, and on both.\(^a\)

| Outcome                         | VT\(^b\)                | Protective MV based on MDP\(^c\) | Both the VT and the MDP | p     | HR (95% CI) | p     | HR (95% CI) | p     |
|---------------------------------|-------------------------|---------------------------------|-------------------------|-------|-------------|-------|-------------|-------|
| In-hospital mortality           | 0.75 (0.43-1.32)        | 0.48 (0.26-0.90)                | 0.53 (0.28-1.01)        | 0.055 |
| ICU mortality                   | 0.78 (0.42-1.47)        | 0.45 (0.24-0.90)                | 0.59 (0.28-1.25)        | 0.151 |
| 28-day mortality                | 0.53 (0.24-1.16)        | 0.41 (0.18-0.94)                | 0.40 (0.17-0.94)        | 0.036 |

\(^a\)Model adjusted for age, Simplified Acute Physiology Score 3, use of vasopressors, PaO\textsubscript{2}/FiO\textsubscript{2}, PEEP, respiratory system compliance, pH, and PaCO\textsubscript{2}. \(^b\)Protective MV based on VT: a VT of < 8 mL/kg of predicted body weight in at least 80% of the 14 measurements performed within the first seven days of MV. \(^c\)Protective MV based on MDP: an MDP of < 15 cmH\textsubscript{2}O in at least 80% of the 14 measurements performed within the first seven days of MV.
when MV was defined as protective on the basis of both the VT and the MDP, the addition of VT therefore being unnecessary. Our results are consistent with those of other studies (16,20) showing correlations between MDP and the outcomes of patients without ARDS. In a study showing no correlation between VT and mortality, a positive correlation was found between MDP and ICU mortality (16). In an observational study of a cohort of 986 patients receiving MV because of an acute neurological condition, Tejerina et al. demonstrated that increased mortality correlated with increased MDP but not with increased VT (20).

We decided to use the term MDP in order to differentiate it from DP, which was initially correlated with better outcomes in ARDS in the study by Amato et al. (8) DP is calculated as the difference between plateau pressure, which is measured at the end of an inspiratory pause, and PEEP. Some authors have used end-inspiratory airway pressure during pressure-controlled MV instead of plateau pressure for calculating DP (15,16,20). Although they are similar or even the same in some cases, especially when there is no significant increase in airway resistance, they are not necessarily always the same. However, MDP will always be equal to or greater than DP and is therefore a useful parameter for monitoring VILI.

To our knowledge, this is the first prospective study analyzing the risk factors associated with the adoption of nonprotective MV in patients at risk for ARDS. The factors associated with nonprotective MV based on the VT were those related to greater patient severity (the SAPS 3 and the PaO2/FiO2 ratio) and lower predicted body weight. The association between nonprotective MV and greater predicted body weight was likely due to priority being given to stabilizing arterial blood gas levels in these patients, possibly to the detriment of protective MV. The association between nonprotective MV and lower predicted body weight was likely due to an inadequate estimate of predicted body weight in shorter patients, given that it is calculated on the basis of patient height. It should be noted that an inappropriate VT setting based on predicted body weight is more likely to occur in women, as indicated by the results of univariate analysis. The factors associated with nonprotective MV based on the MDP were those related to more severe lung disease (pneumonia, lower Crs, and lower PaO2/FiO2) and greater ventilatory demand (lower pH values). These results suggest that not enough attention has been paid to MDP for protective MV, with the MDP increasing when lung mechanics are altered or when there is a need to compensate for acidosis.

Our study has several strengths. First, VT and MDP were measured twice a day during the first 7 days of MV in order to define MV as protective or nonprotective. Previous observational studies of the correlations of VT and DP with mortality in patients without ARDS have collected ventilator settings on a single day, usually the first day of MV (14,15,20). This single assessment, particularly in the case of DP,
may have been much more reflective of the severity of the initial lung disease and its impact on patient outcomes. We believe that our 7-day measurements of $V_t$ and MDP more accurately reflect the correlation of the ventilatory strategy used with the occurrence of VILI and its impact on mortality. In addition, we evaluated the association between nonprotective MV and mortality in a specific group of patients without ARDS, i.e., those with one or more risk factors for developing ARDS. Such patients have worse outcomes (e.g., pulmonary complications and increased mortality) than those without risk factors for ARDS.\(^\text{14,21}\)

Therefore, among patients without ARDS, those with one or more risk factors for ARDS represent a subgroup of patients in whom a lung-protective ventilation strategy is most relevant.

Some limitations of our study should be noted. During the measurements of MDP, particularly in patients receiving pressure support ventilation, we did not consider the possibility of patient inspiratory effort increasing transpulmonary pressure, which is associated with VILI. This limitation is inevitable when esophageal pressure is not monitored in patients making inspiratory efforts. Given the observational nature of our study, it cannot be stated that the correlation between MDP and mortality indicates causality; that is, it cannot be stated that nonprotective MV based on the MDP resulted in increased mortality. Despite multivariate analysis to adjust for potential confounders, a higher MDP may have represented greater patient severity of illness, thus explaining its association with mortality. The sample size may have been insufficient to detect associations between $V_t$ and mortality, given that the power of the study to detect such associations was 39%. However, the fact that an association was found between MDP and mortality—the power of the study to detect such an association being 43%—suggests that MDP is better than $V_t$ to adjust MV for lung-protective ventilation. Because this was a single-center study, our results should be extrapolated with caution.

In conclusion, an increased MDP during the first 7 days of MV was associated with increased mortality, although an increased $V_t$ was not. Therefore, MDP is a parameter that should be considered in mechanically ventilated patients at risk for ARDS. Factors associated with nonprotective MV include lower PaO$_2$/$FIO_2$, lower C$_{ml}$, pneumonia as the reason for initiating MV, higher severity scores, acidosis, and lower predicted body weight. In the presence of one or more of these factors, MV settings should be adjusted to avoid harmful parameters.

REFERENCES

1. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA. 2002;287(3):345-355. https://doi.org/10.1001/jama.287.3.345

2. Esteban A, Ferguson ND, Meade MO, Frutos-Vivar F, Apezteguia C, Brochard L, et al. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med. 2008;177(2):170-177. https://doi.org/10.1164/rccm.2007-690OC

3. Slutsky AS, Ranieri VM. Ventilator-induced lung injury [published correction appears in N Engl J Med. 2014 Apr 24;370(17):1668-9]. N Engl J Med. 2013;369(22):2126-2136. https://doi.org/10.1056/NEJMa1206707

4. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377(6):562-572. https://doi.org/10.1056/NEJMa1808777

5. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1996;338(8):347-354. https://doi.org/10.1056/NEJM199802053380602

6. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308. https://doi.org/10.1056/NEJM200005043421801

7. Needham DM, Yang T, Dinglas VD, Mendez-Tellez PA, Shanholtz C, Sevransky JE, et al. Timing of low tidal volume ventilation and mechanical ventilation and acute respiratory distress syndrome. A prospective cohort study. Am J Respir Crit Care Med. 2015;191(2):177-185. https://doi.org/10.1164/rccm.201409-1598OC

8. Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747-755. https://doi.org/10.1056/NEJMoa1410639

9. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries [published correction appears in JAMA. 2016 Jul 19;316(3):360] [published correction appears in JAMA. 2016 Jul 19;316(3):350]. JAMA. 2016;315(8):788-800. https://doi.org/10.1001/jama.2016.0291

10. Fan E, Sorbo LD, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome [published correction appears in Am J Respir Crit Care Med. 2017 Jun 1;195(11):1540]. Am J Respir Crit Care Med. 2017;195(6):1253-1263. https://doi.org/10.1164/rccm.org/201703-0548ST

11. Webb HH, Tierney DF. Experimental pulmonary edema due to intermittent positive pressure ventilation with high inflation pressures. Protection by positive end-expiratory pressure. Am Rev Respir Dis. 1974;110(5):556-565.

12. Dreyfuss D, Soler P, Basset G, Saunon G. High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure. Am Rev Respir Dis. 1988;137(6):1159-1164. https://doi.org/10.1164/arcc.1988.137.5.1159

13. Determann RM, Royakkers A, Wolthuis EK, Vlaar AP, Choi G, Paulus F, et al. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial. Crit Care. 2010;14(1):R1. https://doi.org/10.1186/cc8230

14. Writing Group for the PrEvENT Investigators, Simonis FD, Serpa Neto A, Binnekade JM, Braber A, Bruin KCM, et al. Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: A Randomized Clinical Trial. JAMA. 2018;320(18):1872-1880. https://doi.org/10.1001/jama.2018.14280

15. Simonis FD, Barbas CSV, Antigas-Raventos A, Canet J, Determann RM, Anstey J, et al. Potentially modifiable respiratory variables contributing to outcome in ICU patients without ARDS: a secondary analysis of PrEvENT. Ann Intensive Care. 2018;8(1):39. https://doi.org/10.1186/s13613-018-0385-7

16. Schmidt MFS, Amaral ACKB, Fan E, Rubenfeld GD, Driving Pressure and Hospital Mortality in Patients Without ARDS: A Cohort Study. Chest. 2018;153(1):46-54. https://doi.org/10.1016/j.chest.2017.10.004
Protective mechanical ventilation in patients with risk factors for ARDS: prospective cohort study

17. Odeyemi YE, Herasevich S, Gong MN, Gajic O. Clinical Strategies to Prevent Acute Respiratory Distress Syndrome. Semin Respir Crit Care Med. 2019;40(1):129-136. https://doi.org/10.1055/s-0039-1683997

18. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533. https://doi.org/10.1001/jama.2012.5669

19. Serpa Neto A, Cardoso SO, Manetta JA, Pereira VG, Espósito DC, Pasqualucci Mde O, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. JAMA. 2012;308(16):1651-1659. https://doi.org/10.1001/ jama.2012.13730

20. Tejerina E, Pelosi P, Muriel A, Peñuelas O, Sutherasan Y, Frutos-Vivar F, et al. Association between ventilatory settings and development of acute respiratory distress syndrome in mechanically ventilated patients due to brain injury. J Crit Care. 2017;38:341-345. https://doi.org/10.1016/j.jcrc.2016.11.010

21. Neto AS, Barbas CSV, Artigas-Raventós A, Canet J, Determann RM, et al. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study. Lancet Respir Med. 2016;4(11):892-893. https://doi.org/10.1016/S2213-2600(16)30305-8